Research ArticleProceedings of the 2017 Viral Clearance Symposium
Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation
Junfen Ma and Thomas R. Kreil
PDA Journal of Pharmaceutical Science and Technology September 2018, 72 (5) 511-515; DOI: https://doi.org/10.5731/pdajpst.2018.009175
Junfen Ma
1Shire, Process Development and Technical Services, 300 Shire Way, Lexington, MA 02421, USA; and
Thomas R. Kreil
2Shire, Global Pathogen Safety, Benatzkygasse 2-6, Vienna 1220, Austria

Reference
- 1.↵
- Knotzer S.,
- Kindermann J.,
- Modrof J.,
- Kreil T. R.
- 2.↵Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin, Q5A (R1).
- 3.↵Guidance for Industry, Q7 Good manufacturing practice guidance for active pharmaceutical ingredients.
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 72, Issue 5
September/October 2018
Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation
Junfen Ma, Thomas R. Kreil
PDA Journal of Pharmaceutical Science and Technology Sep 2018, 72 (5) 511-515; DOI: 10.5731/pdajpst.2018.009175
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.